Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be
used to understand the natural history, underlying immunologic mechanisms, and clinical
implications of central nervous system (CNS) lesions, in particular lesions in the c...
Age: 18 years - 66+
Gender: All
Vancomycin Study in Multiple Sclerosis (MS)
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the
gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in
autoimmunity, including MS. However, the identity of gut microbes modulating
neuro...
Age: 18 - 50 years
Gender: All
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled
study of OCR treatment-discontinuation in patients with early RMS. All eligible participants
will be initiated on OCR using the standard approved administration schedule of two...
Age: 18 - 55 years
Gender: All
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab
as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue
to receive ocrelizumab or are in safety follow-up at the time of the closure of ...
Age: 18 years - 66+
Gender: All
COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis
The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor
impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning
motor cortex. The purpose of this research is to evaluate safety and feasibility....
Age: 21 - 75 years
Gender: All
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which
eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017
McDonald criteria for DIS) will be randomized 1:1 to receive ocrelizumab treatment o...
Age: 18 - 40 years
Gender: All
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
Primary Objective:
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression
in primary progressive multiple sclerosis (PPMS)
Secondary Objectives:
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoi...
Age: 18 - 55 years
Gender: All
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
Primary Objective:
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression
in NRSPMS
Secondary Objective:
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic
resonance imaging (MRI) ...
Age: 18 - 60 years
Gender: All
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing
phase of MS but have minimal impact once the progressive phase has begun. It is unclear if,
in the relapsing phase, there is an advantage of early aggressive therapy with re...
Age: 18 - 60 years
Gender: All
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the
disability of patients suffering from progressive multiple sclerosis and especially those
with gait impairment.
Age: 18 - 65 years
Gender: All
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod
vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
Age: 18 - 55 years
Gender: All
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who
have had a suboptimal response to an adequate course of DMT. Participants will receive
ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (6...
Age: 18 - 55 years
Gender: All
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who
have had a suboptimal response to an adequate course of DMT. Participants will receive
ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (6...
Age: 18 - 55 years
Gender: All